Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022

GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients' survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

Full Report Details at
- http://www.fastmr.com/prod/608207_pharmapoint_chronic_myeloid_leukemia_cml_united.aspx?afid=303

The UK has the second lowest prevalence of CML, and is currently the smallest CML market of the 7MM. Although an increasing prevalence of CML and the launch of Bosulif and Iclusig will act as driving forces of market growth, it will not be enough to compensate for erosion of Gleevec and Sprycel sales once their generic equivalents hit the market.

Scope

* Overview of the CML including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in the UK from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting the UK CML market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for CML
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in the UK

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022